<li>alfentanil<p>alfentanil, citalopram.
Either increases toxicity of the other by serotonin levels. Avoid or Use Alternate Drug.</p></li><li>almotriptan<p>citalopram, almotriptan. Mechanism: unknown. Avoid or Use Alternate Drug. Combination may increase risk of serotonin syndrome. If concomitant treatment with citalopram and a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases.</p></li><li>amitriptyline<p>citalopram and amitriptyline both increase  serotonin levels. Avoid or Use Alternate Drug. Citalopram may increase TCA levels. Increased risk of serotonin syndrome or neuroleptic malignant syndrome. Potential risk for QT prolongation. ECG monitoring is recommended.</p></li><li>amoxapine<p>citalopram and amoxapine both increase  serotonin levels. Avoid or Use Alternate Drug. Citalopram may increase TCA levels. Increased risk of serotonin syndrome or neuroleptic malignant syndrome. Potential risk for QT prolongation. ECG monitoring is recommended.</p></li><li>apixaban<p>citalopram and apixaban both increase  anticoagulation. Avoid or Use Alternate Drug.</p></li><li>buspirone<p>citalopram and buspirone both increase  serotonin levels. Avoid or Use Alternate Drug. Combination may increase risk of serotonin syndrome or neuroleptic malignant syndrome-like reactions.</p></li><li>clarithromycin<p>clarithromycin, citalopram.
Either increases toxicity of the other by QTc interval. Avoid or Use Alternate Drug. To monitor for the prolongation of QT/QTc and/or development  of ventricular tachyarrhythmias the labeling recommends monitoring QT interval or ECG.</p></li><li>clomipramine<p>citalopram and clomipramine both increase  serotonin levels. Avoid or Use Alternate Drug. Citalopram may increase TCA levels. Increased risk of serotonin syndrome or neuroleptic malignant syndrome. Potential risk for QT prolongation. ECG monitoring is recommended.</p></li><li>cocaine<p>citalopram and cocaine both increase  serotonin levels. Avoid or Use Alternate Drug. Combination may increase risk of serotonin syndrome or neuroleptic malignant syndrome-like reactions.</p></li><li>cyclobenzaprine<p>citalopram and cyclobenzaprine both increase  serotonin levels. Avoid or Use Alternate Drug.</p></li><li>desipramine<p>citalopram and desipramine both increase  serotonin levels. Avoid or Use Alternate Drug. Citalopram may increase TCA levels. Increased risk of serotonin syndrome or neuroleptic malignant syndrome. Potential risk for QT prolongation. ECG monitoring is recommended.</p></li><li>desvenlafaxine<p>citalopram and desvenlafaxine both increase  serotonin levels. Avoid or Use Alternate Drug.</p></li><li>dextromethorphan<p>citalopram and dextromethorphan both increase  serotonin levels. Avoid or Use Alternate Drug. Combination may increase risk of serotonin syndrome or neuroleptic malignant syndrome-like reactions.</p></li><li>dolasetron<p>dolasetron, citalopram.
Either increases toxicity of the other by serotonin levels. Avoid or Use Alternate Drug.</p></li><li>doxepin<p>citalopram and doxepin both increase  serotonin levels. Avoid or Use Alternate Drug. Citalopram may increase TCA levels. Increased risk of serotonin syndrome or neuroleptic malignant syndrome. Potential risk for QT prolongation. ECG monitoring is recommended.</p></li><li>duloxetine<p>citalopram and duloxetine both increase  serotonin levels. Avoid or Use Alternate Drug. Combination may increase risk of serotonin syndrome or neuroleptic malignant syndrome-like reactions.</p></li><li>eletriptan<p>citalopram, eletriptan. Mechanism: unknown. Avoid or Use Alternate Drug. Combination may increase risk of serotonin syndrome. If concomitant treatment with citalopram and a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases.</p></li><li>escitalopram<p>citalopram and escitalopram both increase  serotonin levels. Avoid or Use Alternate Drug. Combination may increase risk of serotonin syndrome or neuroleptic malignant syndrome-like reactions. ECG monitoring is recommended, along with drugs that may prolong the QT interval.</p></li><li>fentanyl<p>fentanyl, citalopram.
Either increases toxicity of the other by serotonin levels. Avoid or Use Alternate Drug.</p></li><li>fentanyl intranasal<p>fentanyl intranasal, citalopram.
Either increases toxicity of the other by serotonin levels. Avoid or Use Alternate Drug.</p></li><li>fentanyl iontophoretic transdermal system<p>fentanyl iontophoretic transdermal system, citalopram.
Either increases toxicity of the other by serotonin levels. Avoid or Use Alternate Drug.</p></li><li>fentanyl transdermal<p>fentanyl transdermal, citalopram.
Either increases toxicity of the other by serotonin levels. Avoid or Use Alternate Drug.</p></li><li>fentanyl transmucosal<p>fentanyl transmucosal, citalopram.
Either increases toxicity of the other by serotonin levels. Avoid or Use Alternate Drug.</p></li><li>fluoxetine<p>citalopram and fluoxetine both increase  serotonin levels. Avoid or Use Alternate Drug. Combination may increase risk of serotonin syndrome or neuroleptic malignant syndrome-like reactions. ECG monitoring is recommended, along with drugs that may prolong the QT interval.</p></li><li>fluvoxamine<p>citalopram and fluvoxamine both increase  serotonin levels. Avoid or Use Alternate Drug. Combination may increase risk of serotonin syndrome or neuroleptic malignant syndrome-like reactions.</p></li><li>frovatriptan<p>citalopram, frovatriptan. Mechanism: unknown. Avoid or Use Alternate Drug. Combination may increase risk of serotonin syndrome. If concomitant treatment with citalopram and a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases.</p></li><li>granisetron<p>granisetron, citalopram.
Either increases toxicity of the other by serotonin levels. Avoid or Use Alternate Drug.</p></li><li>haloperidol<p>citalopram will increase the level or effect of haloperidol by  affecting hepatic enzyme CYP2D6 metabolism. Avoid or Use Alternate Drug. Increased risk of serotonin syndrome or neuroleptic malignant syndrome. Potential risk for QT prolongation. ECG monitoring is recommended.</p></li><li>histrelin<p>histrelin increases toxicity of citalopram by QTc interval. Avoid or Use Alternate Drug. Increases risk of torsades de pointes.</p></li><li>hydromorphone<p>hydromorphone, citalopram.
Either increases toxicity of the other by serotonin levels. Avoid or Use Alternate Drug.</p></li><li>hydroxyzine<p>hydroxyzine increases toxicity of citalopram by QTc interval. Avoid or Use Alternate Drug. Increases risk of torsades de pointes.</p></li><li>idelalisib<p>idelalisib will increase the level or effect of citalopram by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Idelalisib is a strong CYP3A inhibitor; avoid coadministration with sensitive CYP3A substrates</p></li><li>imipramine<p>citalopram and imipramine both increase  serotonin levels. Avoid or Use Alternate Drug. Citalopram may increase TCA levels. Increased risk of serotonin syndrome or neuroleptic malignant syndrome. Potential risk for QT prolongation. ECG monitoring is recommended.</p></li><li>ivacaftor<p>ivacaftor increases levels of citalopram by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Ivacaftor and its M1 metabolite has the potential to inhibit CYP3A4, may significantly increase systemic exposure to   3A4 substrates.</p></li><li>l-tryptophan<p>citalopram and l-tryptophan both increase  serotonin levels. Avoid or Use Alternate Drug. Combination may increase risk of serotonin syndrome or neuroleptic malignant syndrome-like reactions.</p></li><li>levomilnacipran<p>citalopram and levomilnacipran both increase  serotonin levels. Avoid or Use Alternate Drug. Combination may increase risk of serotonin syndrome or neuroleptic malignant syndrome-like reactions.</p></li><li>linezolid<p>linezolid and citalopram both increase  serotonin levels. Avoid or Use Alternate Drug. Linezolid may increase serotonin as a result of MAO-A inhibition. If linezolid must be administered, discontinue serotonergic drug immediately and monitor for CNS toxicity. Serotonergic therapy may be resumed 24 hours after last linezolid dose or after 2 weeks of monitoring, whichever comes first.</p></li><li>lorcaserin<p>citalopram and lorcaserin both increase  serotonin levels. Avoid or Use Alternate Drug.</p></li><li>mefloquine<p>mefloquine and citalopram both increase  QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended, along with drugs that may prolong the QT interval.</p></li><li>meperidine<p>meperidine, citalopram.
Either increases toxicity of the other by serotonin levels. Avoid or Use Alternate Drug.</p></li><li>methylene blue<p>methylene blue and citalopram both increase  serotonin levels. Avoid or Use Alternate Drug. Methylene blue may increase serotonin as a result of MAO-A inhibition. If methylene blue must be administered, discontinue serotonergic drug immediately and monitor for CNS toxicity. Serotonergic therapy may be resumed 24 hours after last methylene blue dose or after 2 weeks of monitoring, whichever comes first.</p></li><li>metoclopramide<p>metoclopramide and citalopram both increase  serotonin levels. Avoid or Use Alternate Drug. Additive effects; increased risk for serotonin syndrome, neuroleptic malignant syndrome, dystonia, or other extrapyramidal reactions</p></li><li>milnacipran<p>citalopram and milnacipran both increase  serotonin levels. Avoid or Use Alternate Drug. Combination may increase risk of serotonin syndrome or neuroleptic malignant syndrome-like reactions.</p></li><li>morphine<p>morphine, citalopram.
Either increases toxicity of the other by serotonin levels. Avoid or Use Alternate Drug.</p></li><li>nafarelin<p>nafarelin increases toxicity of citalopram by QTc interval. Avoid or Use Alternate Drug. Increases risk of torsades de pointes.</p></li><li>naratriptan<p>citalopram, naratriptan. Mechanism: unknown. Avoid or Use Alternate Drug. Combination may increase risk of serotonin syndrome. If concomitant treatment with citalopram and a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases.</p></li><li>nefazodone<p>citalopram and nefazodone both increase  serotonin levels. Avoid or Use Alternate Drug.</p></li><li>netupitant/palonosetron<p>netupitant/palonosetron, citalopram.
Either increases toxicity of the other by serotonin levels. Avoid or Use Alternate Drug.</p></li><li>nortriptyline<p>citalopram and nortriptyline both increase  serotonin levels. Avoid or Use Alternate Drug. Citalopram may increase TCA levels. Increased risk of serotonin syndrome or neuroleptic malignant syndrome. Potential risk for QT prolongation. ECG monitoring is recommended.</p></li><li>ondansetron<p>citalopram and ondansetron both increase  QTc interval. Avoid or Use Alternate Drug.  Avoid with congenital long QT syndrome; ECG monitoring recommended with concomitant medications that prolong QT interval, electrolyte abnormalities, CHF, or bradyarrhythmias.<span><br><br></span>ondansetron, citalopram.
Either increases toxicity of the other by serotonin levels. Avoid or Use Alternate Drug.</p></li><li>palonosetron<p>palonosetron, citalopram.
Either increases toxicity of the other by serotonin levels. Avoid or Use Alternate Drug.</p></li><li>panobinostat<p>citalopram and panobinostat both increase  QTc interval. Avoid or Use Alternate Drug. Panobinostat is known to significantly prolong QT interval. Panobinostat prescribing information states use with drugs known to prolong QTc is not recommended.</p></li><li>paroxetine<p>citalopram and paroxetine both increase  serotonin levels. Avoid or Use Alternate Drug. Combination may increase risk of serotonin syndrome or neuroleptic malignant syndrome-like reactions.</p></li><li>phentermine<p>citalopram, phentermine.
Either increases toxicity of the other by Mechanism: unknown. Avoid or Use Alternate Drug. Risk of serotonin syndrome.</p></li><li>pimavanserin<p>citalopram and pimavanserin both increase  QTc interval. Avoid or Use Alternate Drug. Coadministration may increase the risk of QT prolongation and cardiac arrhythmia.</p></li><li>protriptyline<p>citalopram and protriptyline both increase  serotonin levels. Avoid or Use Alternate Drug. Citalopram may increase TCA levels. Increased risk of serotonin syndrome or neuroleptic malignant syndrome. Potential risk for QT prolongation. ECG monitoring is recommended.</p></li><li>rasagiline<p>rasagiline and citalopram both increase  serotonin levels. Avoid or Use Alternate Drug. Combination may increase risk of serotonin syndrome or neuroleptic malignant syndrome-like reactions.</p></li><li>remifentanil<p>remifentanil, citalopram.
Either increases toxicity of the other by serotonin levels. Avoid or Use Alternate Drug.</p></li><li>ribociclib<p>ribociclib and citalopram both increase  QTc interval. Avoid or Use Alternate Drug.</p></li><li>rizatriptan<p>citalopram, rizatriptan. Mechanism: unknown. Avoid or Use Alternate Drug. Combination may increase risk of serotonin syndrome. If concomitant treatment with citalopram and a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases.</p></li><li>sertraline<p>citalopram and sertraline both increase  serotonin levels. Avoid or Use Alternate Drug. Combination may increase risk of serotonin syndrome or neuroleptic malignant syndrome-like reactions.</p></li><li>st john's wort<p>citalopram and st john's wort both increase  serotonin levels. Avoid or Use Alternate Drug. Combination may increase risk of serotonin syndrome or neuroleptic malignant syndrome-like reactions.</p></li><li>sufentanil<p>sufentanil, citalopram.
Either increases toxicity of the other by serotonin levels. Avoid or Use Alternate Drug.</p></li><li>sufentanil sl<p>sufentanil sl, citalopram.
Either increases toxicity of the other by serotonin levels. Avoid or Use Alternate Drug.</p></li><li>sumatriptan<p>citalopram, sumatriptan. Mechanism: unknown. Avoid or Use Alternate Drug. Combination may increase risk of serotonin syndrome. If concomitant treatment with citalopram and a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases.</p></li><li>sumatriptan intranasal<p>citalopram, sumatriptan intranasal. Mechanism: unknown. Avoid or Use Alternate Drug. Combination may increase risk of serotonin syndrome. If concomitant treatment with citalopram and a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases.</p></li><li>sumatriptan transdermal<p>citalopram, sumatriptan transdermal. Mechanism: unknown. Avoid or Use Alternate Drug. Combination may increase risk of serotonin syndrome. If concomitant treatment with citalopram and a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases.</p></li><li>tedizolid<p>tedizolid, citalopram.
Either increases effects of the other by Mechanism: pharmacodynamic synergism. Avoid or Use Alternate Drug. both increase serotonin levels; increased risk of serotonin syndrome.</p></li><li>thioridazine<p>thioridazine and citalopram both increase  QTc interval. Avoid or Use Alternate Drug. Thioridazine should be avoided in combination with drugs that are known to prolong QTc interval.</p></li><li>trimipramine<p>citalopram and trimipramine both increase  serotonin levels. Avoid or Use Alternate Drug. Citalopram may increase TCA levels. Increased risk of serotonin syndrome or neuroleptic malignant syndrome. Potential risk for QT prolongation. ECG monitoring is recommended.</p></li><li>triptorelin<p>triptorelin increases toxicity of citalopram by QTc interval. Avoid or Use Alternate Drug. Increases risk of torsades de pointes.</p></li><li>umeclidinium bromide/vilanterol inhaled<p>citalopram increases toxicity of umeclidinium bromide/vilanterol inhaled by QTc interval. Avoid or Use Alternate Drug. Exercise extreme caution when vilanterol coadministered with drugs that prolong QTc interval; adrenergic agonist effects on the cardiovascular system may be potentiated.</p></li><li>vandetanib<p>citalopram, vandetanib.
Either increases toxicity of the other by QTc interval. Avoid or Use Alternate Drug. Avoid coadministration with drugs known to prolong QT interval;  if a drug known to prolong QT interval must be used, more frequent ECG monitoring is recommended.</p></li><li>vemurafenib<p>vemurafenib and citalopram both increase  QTc interval. Avoid or Use Alternate Drug. Concomitant use of vemurafenib with drugs that  prolong QT interval is not recommended.</p></li><li>venlafaxine<p>citalopram and venlafaxine both increase  serotonin levels. Avoid or Use Alternate Drug. Combination may increase risk of serotonin syndrome or neuroleptic malignant syndrome-like reactions.</p></li><li>vilanterol/fluticasone furoate inhaled<p>citalopram increases toxicity of vilanterol/fluticasone furoate inhaled by QTc interval. Avoid or Use Alternate Drug. Exercise extreme caution when vilanterol coadministered with drugs that prolong QTc interval; adrenergic agonist effects on the cardiovascular system may be potentiated.</p></li><li>vilazodone<p>citalopram, vilazodone.
Either increases toxicity of the other by serotonin levels. Avoid or Use Alternate Drug. Combination may increase risk of serotonin syndrome or neuroleptic malignant syndrome-like reactions.</p></li><li>vortioxetine<p>citalopram increases toxicity of vortioxetine by serotonin levels. Avoid or Use Alternate Drug.</p></li><li>ziprasidone<p>citalopram and ziprasidone both increase  QTc interval. Contraindicated.</p></li><li>zolmitriptan<p>citalopram, zolmitriptan. Mechanism: unknown. Avoid or Use Alternate Drug. Combination may increase risk of serotonin syndrome. If concomitant treatment with citalopram and a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases.</p></li>